
EquityIndex FundsVery High Risk
Regular
NAV (14-Jul-26)
Returns (Since Inception)
Fund Size
₹189 Cr
Expense Ratio
1.05%
ISIN
INF754K01LR3
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+17.90%
— (Cat Avg.)
3 Years
+20.20%
— (Cat Avg.)
5 Years
+12.92%
— (Cat Avg.)
Since Inception
+15.94%
— (Cat Avg.)
| Equity | ₹188.49 Cr | 99.78% |
| Others | ₹0.41 Cr | 0.22% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹20.7 Cr | 10.96% |
| Eli Lilly and Co | Equity | ₹12.93 Cr | 6.85% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹10.79 Cr | 5.71% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹9.84 Cr | 5.21% |
| Divi's Laboratories Ltd | Equity | ₹9.71 Cr | 5.14% |
| Cipla Ltd | Equity | ₹9.14 Cr | 4.84% |
| Dr Reddy's Laboratories Ltd | Equity | ₹8.39 Cr | 4.44% |
| Johnson & Johnson | Equity | ₹8.21 Cr | 4.35% |
| Lupin Ltd | Equity | ₹6.83 Cr | 3.62% |
| Laurus Labs Ltd | Equity | ₹6.58 Cr | 3.48% |
| AbbVie Inc | Equity | ₹5.98 Cr | 3.16% |
| Fortis Healthcare Ltd | Equity | ₹5.8 Cr | 3.07% |
| Torrent Pharmaceuticals Ltd | Equity | ₹5.79 Cr | 3.07% |
| Aurobindo Pharma Ltd | Equity | ₹5.1 Cr | 2.70% |
| Merck & Co Inc | Equity | ₹4.27 Cr | 2.26% |
| Novartis AG ADR | Equity | ₹3.85 Cr | 2.04% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹3.84 Cr | 2.03% |
| Biocon Ltd | Equity | ₹3.35 Cr | 1.77% |
| Mankind Pharma Ltd | Equity | ₹3.24 Cr | 1.72% |
| Ipca Laboratories Ltd | Equity | ₹2.93 Cr | 1.55% |
| Alkem Laboratories Ltd | Equity | ₹2.88 Cr | 1.52% |
| Amgen Inc | Equity | ₹2.62 Cr | 1.39% |
| Zydus Lifesciences Ltd | Equity | ₹2.56 Cr | 1.35% |
| Thermo Fisher Scientific Inc | Equity | ₹2.5 Cr | 1.33% |
| Gland Pharma Ltd | Equity | ₹2.28 Cr | 1.21% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹2.28 Cr | 1.21% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹2.26 Cr | 1.20% |
| Abbott Laboratories | Equity | ₹2.12 Cr | 1.12% |
| Gilead Sciences Inc | Equity | ₹2.11 Cr | 1.11% |
| Novo Nordisk AS ADR | Equity | ₹2.07 Cr | 1.10% |
| Intuitive Surgical Inc | Equity | ₹1.9 Cr | 1.00% |
| Ajanta Pharma Ltd | Equity | ₹1.85 Cr | 0.98% |
| Vertex Pharmaceuticals Inc | Equity | ₹1.7 Cr | 0.90% |
| Danaher Corp | Equity | ₹1.63 Cr | 0.86% |
| Narayana Hrudayalaya Ltd | Equity | ₹1.48 Cr | 0.79% |
| Stryker Corp | Equity | ₹1.46 Cr | 0.77% |
| Medtronic PLC | Equity | ₹1.35 Cr | 0.71% |
| Global Health Ltd | Equity | ₹1.31 Cr | 0.69% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.15 Cr | 0.61% |
| Regeneron Pharmaceuticals Inc | Equity | ₹0.87 Cr | 0.46% |
| Anthem Biosciences Ltd | Equity | ₹0.81 Cr | 0.43% |
| Becton Dickinson & Co | Equity | ₹0.58 Cr | 0.31% |
| Agilent Technologies Inc | Equity | ₹0.5 Cr | 0.27% |
| Waters Corp | Equity | ₹0.5 Cr | 0.26% |
| IQVIA Holdings Inc | Equity | ₹0.44 Cr | 0.23% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.32 Cr | 0.17% |
| Net Receivables/(Payables) | Cash - Collateral | ₹0.09 Cr | 0.05% |
| Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Large Cap Stocks
29.71%
Mid Cap Stocks
36.47%
Small Cap Stocks
3.11%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹188.49 Cr | 99.78% |
Standard Deviation
This fund
12.32%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
1.03
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
ISIN INF754K01LR3 | Expense Ratio 1.05% | Exit Load No Charges | Fund Size ₹189 Cr | Age 5 years 8 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,20,746 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments